124 related articles for article (PubMed ID: 38508335)
1. The Association Between Sputum Culture Conversion and Mortality in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Lee JK; Kim S; Chong YP; Lee HJ; Shim TS; Jo KW
Chest; 2024 Mar; ():. PubMed ID: 38508335
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Treatment Outcomes of Cavitary Mycobacterium avium Complex Pulmonary Disease with Streptomycin or Amikacin Use.
Kim SM; Chong YP; Lee HJ; Shim TS; Jo KW
Microbiol Spectr; 2023 Jun; 11(3):e0474122. PubMed ID: 37022189
[TBL] [Abstract][Full Text] [Related]
3. Treatment Outcomes of Cavitary Nodular Bronchiectatic-Type Mycobacterium avium Complex Pulmonary Disease.
Chae G; Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0226121. PubMed ID: 35950842
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Treatment Outcome of Progressive
Fukushima K; Kitada S; Abe Y; Yamamoto Y; Matsuki T; Kagawa H; Oshitani Y; Tsujino K; Yoshimura K; Miki M; Miki K; Kida H
J Clin Med; 2020 May; 9(5):. PubMed ID: 32370226
[TBL] [Abstract][Full Text] [Related]
5. Microbiological Cure at Treatment Completion Is Associated With Longer Survival in Patients With Mycobacterium avium Complex Pulmonary Disease.
Kim JY; Park J; Choi Y; Kim TS; Kwak N; Yim JJ
Chest; 2023 Nov; 164(5):1108-1114. PubMed ID: 37423256
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcome with Standard Regimen plus Clofazimine or Moxifloxacin in Cavitary Mycobacterium avium Complex Pulmonary Disease.
Park YE; Chong YP; Lee HJ; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0052822. PubMed ID: 36326247
[TBL] [Abstract][Full Text] [Related]
7. Outcome of shorter treatment duration in non-cavitary nodular bronchiectatic
Park YE; Chong YP; Kim YJ; Kim OH; Kwon BS; Shim TS; Jo KW
J Thorac Dis; 2020 Mar; 12(3):338-348. PubMed ID: 32274100
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment outcomes between intermittent and daily regimens in non-cavitary nodular bronchiectatic-type
Jung J; Chong YP; Lee HJ; Shim TS; Jo K-W
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0100323. PubMed ID: 37843254
[TBL] [Abstract][Full Text] [Related]
9. Redevelopment after spontaneous sputum conversion in noncavitary nodular bronchiectatic Mycobacterium avium complex lung disease.
Kim OH; Chong YP; Shim TS; Jo KW
J Infect Chemother; 2021 Aug; 27(8):1156-1161. PubMed ID: 33745810
[TBL] [Abstract][Full Text] [Related]
10. Antibiotic Maintenance and Redevelopment of Nontuberculous Mycobacteria Pulmonary Disease after Treatment of Mycobacterium avium Complex Pulmonary Disease.
Zo S; Kim H; Kwon OJ; Jhun BW
Microbiol Spectr; 2022 Aug; 10(4):e0108822. PubMed ID: 35950873
[TBL] [Abstract][Full Text] [Related]
11. Association Between Duration of Aminoglycoside Treatment and Outcome of Cavitary Mycobacterium avium Complex Lung Disease.
Kim OH; Kwon BS; Han M; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Clin Infect Dis; 2019 May; 68(11):1870-1876. PubMed ID: 30239615
[TBL] [Abstract][Full Text] [Related]
12. Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.
Moon SM; Jhun BW; Baek SY; Kim S; Jeon K; Ko RE; Shin SH; Lee H; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ
Respir Med; 2019 May; 151():1-7. PubMed ID: 31047103
[TBL] [Abstract][Full Text] [Related]
13. The natural history of non-cavitary nodular bronchiectatic Mycobacterium avium complex lung disease.
Kwon BS; Lee JH; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Shim TS; Jo KW
Respir Med; 2019 Apr; 150():45-50. PubMed ID: 30961950
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes and relapse in patients with
Chang CL; Yu CJ; Hsueh PR; Chien JY
Microbiol Spectr; 2023 Sep; 11(5):e0164023. PubMed ID: 37754771
[TBL] [Abstract][Full Text] [Related]
15. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
[TBL] [Abstract][Full Text] [Related]
16. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease.
Ito Y; Hirai T; Maekawa K; Fujita K; Imai S; Tatsumi S; Handa T; Matsumoto H; Muro S; Niimi A; Mishima M
Int J Tuberc Lung Dis; 2012; 16(3):408-14. PubMed ID: 22230733
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of the interstitial lung disease subtype of unclassifiable type Mycobacterium avium complex pulmonary disease.
Park YE; Lee JH; Chong YP; Lee HJ; Kim HC; Song JW; Shim TS; Jo KW
J Infect Chemother; 2022 Aug; 28(8):1112-1118. PubMed ID: 35400550
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Fluoroquinolones as Substitutes for Ethambutol or Rifampin in the Treatment of Mycobacterium avium Complex Pulmonary Disease According to Radiologic Types.
Lee JH; Park YE; Chong YP; Shim TS; Jo KW
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0152221. PubMed ID: 34930036
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio According to the Radiologic Severity of
Kim MA; Park YE; Chong YP; Shim TS; Jo KW
J Korean Med Sci; 2022 Oct; 37(40):e292. PubMed ID: 36254530
[TBL] [Abstract][Full Text] [Related]
20. Cavity formation and its predictors in noncavitary nodular bronchiectatic Mycobacterium avium complex pulmonary disease.
Han DW; Jo KW; Kim OH; Shim TS
Respir Med; 2021 Apr; 179():106340. PubMed ID: 33618079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
